Kayne Anderson Rudnick Investment Management’s AbbVie ABBV Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28.5M	Buy	113,217 +1,319	+1%	+$284K	0.09%	160
2026 Q1	$24.3M	Sell	111,898 -10,209	-8%	-$2.26M	0.07%	173
2025 Q4	$27.9M	Sell	122,107 -1,933	-2%	-$440K	0.07%	171
2025 Q3	$28.7M	Sell	124,040 -7,902	-6%	-$1.61M	0.07%	177
2025 Q2	$24.5M	Buy	131,942 +2,007	+2%	+$373K	0.06%	181
2025 Q1	$27.2M	Sell	129,935 -3,965	-3%	-$771K	0.07%	175
2024 Q4	$23.8M	Sell	133,900 -4,384	-3%	-$806K	0.05%	191
2024 Q3	$27.3M	Sell	138,284 -5,127	-4%	-$957K	0.06%	175
2024 Q2	$24.6M	Sell	143,411 -2,918	-2%	-$483K	0.06%	184
2024 Q1	$26.6M	Sell	146,329 -3,232	-2%	-$557K	0.06%	183
2023 Q4	$23.2M	Sell	149,561 -8,251	-5%	-$1.2M	0.06%	186
2023 Q3	$23.5M	Sell	157,812 -4,190	-3%	-$615K	0.07%	175
2023 Q2	$21.8M	Sell	162,002 -3,626	-2%	-$532K	0.06%	187
2023 Q1	$26.4M	Sell	165,628 -1,324	-0.8%	-$202K	0.08%	165
2022 Q4	$27M	Buy	166,952 +803	+0.5%	+$123K	0.08%	166
2022 Q3	$22.3M	Buy	166,149 +84,885	+104%	+$12.2M	0.07%	175
2022 Q2	$12.4M	Buy	81,264 +215	+0.3%	+$32.9K	0.04%	224
2022 Q1	$13.1M	Buy	81,049 +77,880	+2,458%	+$11.3M	0.03%	231
2021 Q4	$429K	Buy	3,169 +19	+0.6%	+$2.24K	﹤0.01%	375
2021 Q3	$340K	Hold	3,150	–	–	﹤0.01%	376
2021 Q2	$355K	Hold	3,150	–	–	﹤0.01%	374
2021 Q1	$341K	Buy	3,150 +54	+2%	+$5.78K	﹤0.01%	370
2020 Q4	$332K	Hold	3,096	–	–	﹤0.01%	365
2020 Q3	$271K	Buy	3,096 +200	+7%	+$18.8K	﹤0.01%	361
2020 Q2	$284K	Buy	2,896 +9	+0.3%	+$792	﹤0.01%	347
2020 Q1	$220K	Hold	2,887	–	–	﹤0.01%	348
2019 Q4	$256K	Buy	2,887 +48	+2%	+$3.98K	﹤0.01%	343
2019 Q3	$215K	Hold	2,839	–	–	﹤0.01%	341
2019 Q2	$206K	Hold	2,839	–	–	﹤0.01%	334
2019 Q1	$229K	Hold	2,839	–	–	﹤0.01%	328
2018 Q4	$262K	Hold	2,839	–	–	﹤0.01%	344
2018 Q3	$269K	Hold	2,839	–	–	﹤0.01%	320
2018 Q2	$263K	Sell	2,839 -1,000	-26%	-$97.7K	﹤0.01%	326
2018 Q1	$363K	Buy	3,839 +166	+5%	+$18.2K	﹤0.01%	329
2017 Q4	$355K	Buy	3,673 +373	+11%	+$35.2K	﹤0.01%	322
2017 Q3	$293K	Hold	3,300	–	–	﹤0.01%	326
2017 Q2	$239K	Sell	3,300 -2,488	-43%	-$167K	﹤0.01%	330
2017 Q1	$377K	Hold	5,788	–	–	﹤0.01%	326
2016 Q4	$362K	Hold	5,788	–	–	﹤0.01%	317
2016 Q3	$365K	Hold	5,788	–	–	﹤0.01%	320
2016 Q2	$358K	Hold	5,788	–	–	0.01%	315
2016 Q1	$331K	Hold	5,788	–	–	0.01%	306
2015 Q4	$343K	Hold	5,788	–	–	0.01%	311
2015 Q3	$315K	Sell	5,788 -100	-2%	-$6.51K	0.01%	308
2015 Q2	$396K	Buy	5,888 +100	+2%	+$6.53K	0.01%	282
2015 Q1	$339K	Hold	5,788	–	–	0.01%	288
2014 Q4	$379K	Hold	5,788	–	–	0.01%	293
2014 Q3	$334K	Hold	5,788	–	–	0.01%	289
2014 Q2	$327K	Hold	5,788	–	–	0.01%	292
2014 Q1	$298K	Hold	5,788	–	–	0.01%	284
2013 Q4	$306K	Hold	5,788	–	–	0.01%	274
2013 Q3	$259K	Hold	5,788	–	–	﹤0.01%	265
2013 Q2	$239K	Buy	+5,788	New	+$253K	﹤0.01%	259

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's ABBV Position: Q2 2026 in Review

Kayne Anderson Rudnick Investment Management increased its AbbVie (ABBV) stake by 1.2% in Q2 2026, buying an estimated $284K and bringing the position to 113,217 shares worth $28.5M. The position accounts for 0.09% of the portfolio, ranked #160.

Kayne Anderson Rudnick Investment Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $28.7M in Q3 2025. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Kayne Anderson Rudnick Investment Management held 113,217 shares of AbbVie worth $28.5M as of Q2 2026.
Kayne Anderson Rudnick Investment Management bought 1,319 AbbVie shares in Q2 2026, an estimated $284K.
AbbVie made up 0.09% of Kayne Anderson Rudnick Investment Management's portfolio in Q2 2026, its #160 holding.
Kayne Anderson Rudnick Investment Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
Kayne Anderson Rudnick Investment Management's AbbVie position peaked at $28.7M in Q3 2025.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.